Symbiotec Pharmalab Q2FY27 PAT Jumps 169% to ₹52 Crore on 43% Revenue Growth
Symbiotec Pharmalab reported a 169% YoY jump in Q2 FY27 PAT to ₹52 crore on 43% revenue growth to ₹280 crore. H1 FY27 PAT increased 34% to ₹66 crore on 25% revenue growth to ₹498 crore. The company secured milestone revenue of ₹53 crore from US DCV product licensing and expects new businesses to commence within 6-12 months.
The substantial increase in revenue and PAT, coupled with successful regulatory approvals and new business agreements, indicates a significant positive impact on the company's financial performance and future prospects.
The company reported significant year-on-year growth in revenue and profit, along with strong operational highlights and positive management commentary on future outlook.
Symbiotec Pharmalab Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company reported a strong performance with consolidated revenue growing by 43% year-on-year to ₹280 crore for Q2 FY27. Profit After Tax (PAT) surged by 169% to ₹52 crore during the same period.
For the half-year ended September 30, 2026 (H1 FY27), consolidated revenues increased by 25% to ₹498 crore, while PAT saw a 34% rise to ₹66 crore. The API business also demonstrated robust growth, with operating revenue up 16% to ₹227 crore in Q2 FY27 and EBIDTA increasing by 21% to ₹71 crore. API gross margins remained strong, above 60%, and EBIDTA margins were steady at approximately 30% driven by revenue growth and a favorable sales mix.
Key operational highlights include the successful completion of four major regulatory audits (EUGMP and USFDA) for its Rau and Pithampur plants. The company also recognized milestone-based revenue of ₹53 crore from a licensing agreement for two DCV products in the US, with commercial supplies expected to commence next year. The first molecule ANDA for DCV has been filed and accepted by the USFDA, with the second ANDA filing scheduled for Q4 FY27, qualifying for expedited Priority Review.
In the Biotech-CDMO Services segment, Symbiotec has a 10-year take-or-pay agreement with a US-based Alternate Protein player and is in advanced stages for a similar agreement with a Europe-based player. For its Insulin Drug Substance, a 5-year take-or-pay agreement is in place, with regulatory approval filings expected in Q4 FY27/Q1 FY28.
The company has planned a total gross capex of approximately ₹1,672 crore by the end of FY27, with 61% (₹1,000 crore) invested in new revenue-generating businesses, a majority of which have contracted revenues expected to commence in the next 6-12 months. As of September 30, 2026, the net debt stood at approximately ₹314 crore.
Mr. Anil Satwani, Chairman & Managing Director, expressed confidence in the company's growth outlook, highlighting the strong business momentum, the scaling up of emerging growth engines, and the potential for the Injectables and CDMO businesses to reach a size comparable to the established API business.
What to do with a filing like this
Symbiotec Pharmalab Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Symbiotec Pharmalab Limited. Read the original for the full detail.